Key Points
-
Moderna is close to gaining approval for its mRNA-1010 influenza vaccine.
-
Krystal Biotech’s Vyjuvek for dystrophic epidermolysis bullosa (DEB) has led to a streak of 11 quarters of positive earnings.
-
AMD’s stock has surged by 129% in 2023, as the company positions itself in the growing AI market.
The S&P 500 is up 8% year-to-date, with Moderna, Krystal Biotech, and Advanced Micro Devices (AMD) notably outperforming the market. Moderna (NASDAQ: MRNA) is advancing towards approval for its influenza vaccine, mRNA-1010, targeting elderly patients at risk due to low current vaccine efficacy. Krystal Biotech (NASDAQ: KRYS) has seen significant revenue growth from its FDA-approved gene therapy, Vyjuvek, and continues to expand its market presence. AMD (NASDAQ: AMD) has increased its market share in desktop CPUs to 33.2% and is poised to capitalize on the $200 billion market for AI-related CPUs, following a remarkable 129% share price increase this year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
